{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:05:42Z","timestamp":1778799942260,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373415"],"award-info":[{"award-number":["82373415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Clinical Research Center for CANCER","award":["2022E50008"],"award-info":[{"award-number":["2022E50008"]}]},{"name":"Provincial Key R&D Program of Zhejiang Province","award":["2021C03125"],"award-info":[{"award-number":["2021C03125"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03846-8","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T01:01:16Z","timestamp":1727917276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget\u2019s disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget\u2019s disease patients"],"prefix":"10.1007","volume":"73","author":[{"given":"Jiawen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"3846_CR1","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41422-020-0334-5","volume":"30","author":"Y Song","year":"2020","unstructured":"Song Y, Guerrero-Juarez CF, Chen Z et al (2020) The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget\u2019s disease. Cell Res 30:854\u2013872. https:\/\/doi.org\/10.1038\/s41422-020-0334-5","journal-title":"Cell Res"},{"key":"3846_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1590\/abd1806-4841.20153189","volume":"90","author":"LL Lopes Filho","year":"2015","unstructured":"Lopes Filho LL, Lopes IM, Lopes LR, Enokihara MM, Michalany AO, Matsunaga N (2015) Mammary and extramammary Paget\u2019s disease. Bras Dermatol 90:225\u2013231. https:\/\/doi.org\/10.1590\/abd1806-4841.20153189","journal-title":"Bras Dermatol"},{"key":"3846_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.det.2010.08.002","volume":"28","author":"C Lam","year":"2010","unstructured":"Lam C, Funaro D (2010) Extramammary Paget\u2019s disease: summary of current knowledge. Dermatol Clin 28:807\u2013826. https:\/\/doi.org\/10.1016\/j.det.2010.08.002","journal-title":"Dermatol Clin"},{"key":"3846_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2559.1990.tb00714.x","volume":"17","author":"L Keatings","year":"1990","unstructured":"Keatings L, Sinclair J, Wright C, Corbett IP, Watchorn C, Hennessy C, Angus B, Lennard T, Horne CH (1990) c-erbB-2 oncoprotein expression in mammary and extramammary Paget\u2019s disease: an immunohistochemical study. Histopathology 17:243\u2013247. https:\/\/doi.org\/10.1111\/j.1365-2559.1990.tb00714.x","journal-title":"Histopathology"},{"key":"3846_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2023) NCCN Guidelines(R) insights: breast Cancer, Version 4.2023. J Natl Compr Canc Netw 21:594\u2013608. https:\/\/doi.org\/10.6004\/jnccn.2023.0031","journal-title":"J Natl Compr Canc Netw"},{"key":"3846_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s11864-021-00923-3","volume":"23","author":"H Hashimoto","year":"2022","unstructured":"Hashimoto H, Ito T (2022) Current management and treatment of Extramammary Paget\u2019s Disease. Curr Treat Options Oncol 23:818\u2013830. https:\/\/doi.org\/10.1007\/s11864-021-00923-3","journal-title":"Curr Treat Options Oncol"},{"key":"3846_CR7","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:2042\u20130226 (Electronic). https:\/\/doi.org\/10.1038\/s41423-020-0488-6","journal-title":"Cell Mol Immunol"},{"key":"3846_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","volume":"5","author":"GL Szeto","year":"2019","unstructured":"Szeto GL, Finley SD (2019) Integrative approaches to cancer immunotherapy. Trends Cancer 5:400\u2013410. https:\/\/doi.org\/10.1016\/j.trecan.2019.05.010","journal-title":"Trends Cancer"},{"key":"3846_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"3846_CR10","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMc1808251","volume":"379","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Pardoll DM (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 379:e14. https:\/\/doi.org\/10.1056\/NEJMc1808251","journal-title":"N Engl J Med"},{"key":"3846_CR11","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"3846_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"key":"3846_CR13","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S (2023) Cancer immunotherapies: advances and bottlenecks. Front Immunol 14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476","journal-title":"Front Immunol"},{"key":"3846_CR14","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.1067\/mjd.2002.126584","volume":"47","author":"JC Zampogna","year":"2002","unstructured":"Zampogna JC, Flowers FP, Roth WI, Hassenein AM (2002) Treatment of primary limited cutaneous extramammary Paget\u2019s disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 47:S229\u2013S235. https:\/\/doi.org\/10.1067\/mjd.2002.126584","journal-title":"J Am Acad Dermatol"},{"key":"3846_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00404-010-1653-4","volume":"283","author":"E Tonguc","year":"2011","unstructured":"Tonguc E, Gungor T, Var T, Ozat M, Sahin I, Sirvan L (2011) Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature. Arch Gynecol Obstet 283:97\u2013101. https:\/\/doi.org\/10.1007\/s00404-010-1653-4","journal-title":"Arch Gynecol Obstet"},{"key":"3846_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060754","author":"SH Mauzo","year":"2019","unstructured":"Mauzo SH, Tetzlaff MT, Milton DR et al (2019) Expression of PD-1 and PD-L1 in extramammary paget disease: implications for immune-targeted therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11060754","journal-title":"Cancers (Basel)"},{"key":"3846_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/cup.13768","volume":"47","author":"K Furlan","year":"2020","unstructured":"Furlan K, Rohra P, Mir F, Gattuso P (2020) Non-human-papillomavirus-related malignancies of the vulva: a clinicopathological study. J Cutan Pathol 47:917\u2013922. https:\/\/doi.org\/10.1111\/cup.13768","journal-title":"J Cutan Pathol"},{"key":"3846_CR18","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cam4.2820","volume":"9","author":"Z Gatalica","year":"2020","unstructured":"Gatalica Z, Vranic S, Kruslin B et al (2020) Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget\u2019s disease. Cancer Med 9:1441\u20131450. https:\/\/doi.org\/10.1002\/cam4.2820","journal-title":"Cancer Med"},{"key":"3846_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamasurg.2018.0501","volume":"153","author":"KM Doll","year":"2018","unstructured":"Doll KM, Rademaker A, Sosa JA (2018) Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg 153:588\u2013589. https:\/\/doi.org\/10.1001\/jamasurg.2018.0501","journal-title":"JAMA Surg"},{"key":"3846_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559","journal-title":"BMC Bioinformatics"},{"key":"3846_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118","journal-title":"OMICS"},{"key":"3846_CR22","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3846_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7","journal-title":"BMC Bioinformatics"},{"key":"3846_CR24","doi-asserted-by":"publisher","unstructured":"Lyu F, Han FR, Ge CL, Mao WK, Chen L, Hu HP, Chen GG, Lang QL, Fang C (2023) OmicStudio: a composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication. IMETA 2. https:\/\/doi.org\/10.1002\/imt2.85","DOI":"10.1002\/imt2.85"},{"key":"3846_CR25","doi-asserted-by":"publisher","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng D, Ye Z, Shen R et al (2021) IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol 12:687975. https:\/\/doi.org\/10.3389\/fimmu.2021.687975","journal-title":"Front Immunol"},{"key":"3846_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18:248\u2013262. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019","journal-title":"Cell Rep"},{"key":"3846_CR27","doi-asserted-by":"publisher","unstructured":"Bagaev A, Kotlov N, Nomie K et al (2021) Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39 845\u2009\u2013\u200965 e7. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.014","DOI":"10.1016\/j.ccell.2021.04.014"},{"key":"3846_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/jamaoncol.2021.7148","volume":"8","author":"N Kibbi","year":"2022","unstructured":"Kibbi N, Owen JL, Worley B et al (2022) Evidence-based clinical practice guidelines for Extramammary Paget Disease. JAMA Oncol 8:618\u2013628. https:\/\/doi.org\/10.1001\/jamaoncol.2021.7148","journal-title":"JAMA Oncol"},{"issue":"Electronic","key":"3846_CR29","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1186\/s12885-016-2622-5","volume":"16","author":"M Tolia","year":"2016","unstructured":"Tolia M, Tsoukalas N, Sofoudis C, Giaginis C, Spyropoulou D, Kardamakis D, Kouloulias V, Kyrgias G (2016) Primary extramammary invasive Paget\u2019s vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy? BMC Cancer 16(Electronic):1471\u20132407. https:\/\/doi.org\/10.1186\/s12885-016-2622-5","journal-title":"BMC Cancer"},{"key":"3846_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/annonc\/mdt478","volume":"25","author":"M Hata","year":"2014","unstructured":"Hata M, Koike I, Wada H et al (2014) Radiation therapy for extramammary Paget\u2019s disease: treatment outcomes and prognostic factors. Ann Oncol 25:291\u2013297. https:\/\/doi.org\/10.1093\/annonc\/mdt478","journal-title":"Ann Oncol"},{"key":"3846_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2133.2007.08314.x","volume":"158","author":"N Hatta","year":"2008","unstructured":"Hatta N, Yamada M, Hirano T, Fujimoto A, Morita R (2008) Extramammary Paget\u2019s disease: treatment, prognostic factors and outcome in 76 patients. Br J Dermatol 158:313\u2013318. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08314.x","journal-title":"Br J Dermatol"},{"key":"3846_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae097","author":"I Hirai","year":"2024","unstructured":"Hirai I, Tanese K, Nakamura Y et al (2024) Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget\u2019s disease (EMPD-HER2DOC). Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae097","journal-title":"Oncologist"},{"key":"3846_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","volume":"22","author":"CM Laumont","year":"2022","unstructured":"Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH (2022) Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer 22:414\u2013430. https:\/\/doi.org\/10.1038\/s41568-022-00466-1","journal-title":"Nat Rev Cancer"},{"key":"3846_CR34","doi-asserted-by":"publisher","first-page":"1860586","DOI":"10.1080\/2162402X.2020.1860586","volume":"10","author":"J Budczies","year":"2021","unstructured":"Budczies J, Kirchner M, Kluck K et al (2021) A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. Oncoimmunology 10:1860586. https:\/\/doi.org\/10.1080\/2162402X.2020.1860586","journal-title":"Oncoimmunology"},{"key":"3846_CR35","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-21-1130","volume":"28","author":"M Lauss","year":"2022","unstructured":"Lauss M, Donia M, Svane IM, Jonsson G (2022) B cells and tertiary lymphoid structures: friends or foes in Cancer Immunotherapy? Clin Cancer Res 28:1751\u20131758. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1130","journal-title":"Clin Cancer Res"},{"key":"3846_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/2326-6066.CIR-18-0517","volume":"7","author":"HH Workel","year":"2019","unstructured":"Workel HH, Lubbers JM, Arnold R et al (2019) A transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol Res 7:784\u2013796. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0517","journal-title":"Cancer Immunol Res"},{"key":"3846_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","volume":"16","author":"SS Wang","year":"2019","unstructured":"Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L (2019) Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol 16:6\u201318. https:\/\/doi.org\/10.1038\/s41423-018-0027-x","journal-title":"Cell Mol Immunol"},{"key":"3846_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q (2023) Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med 20:181\u2013195. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0002","journal-title":"Cancer Biol Med"},{"key":"3846_CR39","doi-asserted-by":"publisher","unstructured":"Heemskerk N, Gruijs M, Temming AR et al (2021) Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity. J Clin Invest 131. https:\/\/doi.org\/10.1172\/JCI134680","DOI":"10.1172\/JCI134680"},{"key":"3846_CR40","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","volume":"12","author":"AT Ruffin","year":"2021","unstructured":"Ruffin AT, Cillo AR, Tabib T et al (2021) B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun 12:3349. https:\/\/doi.org\/10.1038\/s41467-021-23355-x","journal-title":"Nat Commun"},{"key":"3846_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","volume":"109","author":"X Wang","year":"2019","unstructured":"Wang X, Wang G, Wang Z et al (2019) PD-1-expressing B cells suppress CD4(+) and CD8(+) T cells via PD-1\/PD-L1-dependent pathway. Mol Immunol 109:20\u201326. https:\/\/doi.org\/10.1016\/j.molimm.2019.02.009","journal-title":"Mol Immunol"},{"key":"3846_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","volume":"6","author":"X Xiao","year":"2016","unstructured":"Xiao X, Lao XM, Chen MM et al (2016) PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov 6:546\u2013559. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1408","journal-title":"Cancer Discov"},{"key":"3846_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reynies A, Keung EZ et al (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577:556\u2013560. https:\/\/doi.org\/10.1038\/s41586-019-1906-8","journal-title":"Nature"},{"key":"3846_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549\u2013555. https:\/\/doi.org\/10.1038\/s41586-019-1922-8","journal-title":"Nature"},{"key":"3846_CR45","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1158\/1078-0432.CCR-11-0207","volume":"17","author":"Q Li","year":"2011","unstructured":"Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17:4987\u20134995. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0207","journal-title":"Clin Cancer Res"},{"key":"3846_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B et al (2023) Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-Mutant Melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol 41:186\u2013197. https:\/\/doi.org\/10.1200\/JCO.22.01763","journal-title":"J Clin Oncol"},{"key":"3846_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Mandala M, Ferrucci PF et al (2023) Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-Mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol 41:212\u2013221. https:\/\/doi.org\/10.1200\/JCO.21.02961","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03846-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T12:04:42Z","timestamp":1731758682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03846-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3846"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03846-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"252"}}